BrightGene Bio-Medical Technology (Suzhou) Co., Ltd.

A research-based pharmaceutical companyBrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market and Chinese market.Established in 2001, BrightGene boasts cutting- edging R&D expertise and commercial manufacturing capabilities to serve our patients and clients around the globe.We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, orally available oxyntomodulin analog for NASH and novel non-antibody dependent tumor targeting conjugates for brain and other types of cancer.In parallel, we have also developed a special generic pipeline of extremely challenging molecules like Eribulin, Trabectedin, Fondaparinux, Caspofungin and non-biological macromolecules such as Ferumoxytol and Ferric pyrophosphate citrate.We pride ourselves in exceptional R&D capability and robust project execution. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.